- President & Chief Executive Officer (CEO)：
- Tetsuya Mishima
Development of innovative drugs in order to realize a disease-free society.
Epigeneron, Inc. develops drugs which target intractable diseases caused by abnormal regulation of genome functions such as transcription and epigenetic regulation. They also provide services for the development of drugs against such diseases. One of Epigeneron's core technologies is locus-specific chromatin immunoprecipitation (locus-specific ChIP) that enables isolation of specific genomic regions while preserving interactions between the target genomic regions and their binding molecules. This technology allows identification of molecules interacting with specific genomic regions inside the cells. Locus-specific ChIP is currently being utilized for drug target screening of intractable diseases, including cancer, fibrosis, disorders of the central nervous system, and infectious diseases caused by abnormal expression of causative genes or effector genes of pathogens. Epigeneron will continue to be the driver of innovation in drug development, targeting the events in the nucleus encompassing epigenetic drugs and enhancer drugs. In addition, Epigeneron is also active in the development of novel biotechnologies based on molecular biology.
Dr. Hodaka Fujii, one of the founders and CSO of Epigeneron, Inc. and a Professor of Hirosaki University Graduate School of Medicine, and his colleagues have developed locus-specific ChIP technology which enables biochemical analysis of specific genomic regions. Using this technology, Epigeneron focuses on development of drugs against intractable diseases caused by abnormal functions of the genome.
Locus-specific ChIP and related novel innovative technologies for drug discovery and other fields. Epigeneron’s technology is poised to tackle both existing and emerging healthcare issues.
UTEC’s value add
UTEC provides financial support, assistance in patent enhancement, search for management talent, development of business model, etc.